Results 81 to 90 of about 245,125 (261)

Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer

İstanbul Medical Journal
Introduction: Adding targeted agents to chemotherapy for metastatic colorectal cancer increases survival. There have been no clinical trials in older populations comparing the efficacy of the targeted agents.
Ender Doğan, Sedat Tarık Fırat, Murat Eser, Oktay Bozkurt, Mevlüde İnanç, Metin Özkan   +5 more
doaj   +1 more source

Anti-VEGF and Beyond [PDF]

Journal of Ophthalmology, 2017
T. Bertelmann, H. Kaymak, F. T. A. Kretz, M. J. Koss   +3 more
openaire   +3 more sources

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Is There a Relationship Between Use of Anti-Vascular Endothelial Growth Factor Agents and Atrophic Changes in Age-Related Macular Degeneration Patients?

Türk Oftalmoloji Dergisi, 2018
Choroidal neovascularization due to age-related macular degeneration (AMD) is currently treated successfully with anti-vascular endothelial growth factor (VEGF) intravitreal agents.
Süleyman Kaynak, Mahmut Kaya, Derya Kaya   +2 more
doaj   +1 more source

Targeting METTL3 Attenuates Thyroid Inflammatory Injury by Restoring Th17/Treg Balance through a YTHDC2‐m6A‐Dependent KDR/VEGFA Loop

Advanced Science, EarlyView.
METTL3‐mediated m6A modification stabilizes KDR/Kdr mRNA through YTHDC2, amplifying the VEGFA‐KDR feedback loop and disturbing Th17/Treg balance. This pathway promotes persistent inflammation and tissue damage in patients with AIT, and inhibiting the METTL3‐KDR axis effectively disrupts this circuit, alleviating thyroid tissue injury and disease ...
Qingyi Hu, Huan Liu, Anwen Ren, Zimei Tang, Jie Tan, Wen Yang, Jie Ming, Tao Huang   +7 more
wiley   +1 more source

Clinical preferences and trends of anti‐vascular endothelial growth factor treatments for diabetic macular edema in Japan

Journal of Diabetes Investigation, 2019
Aims/Introduction To determine the current clinical preferences of anti‐vascular endothelial growth factor (VEGF) treatment protocols for diabetic macular edema (DME) in Japan. Materials and Methods This was a descriptive cross‐sectional study.
Masahiko Sugimoto, Hideyuki Tsukitome, Fumiki Okamoto, Tetsuro Oshika, Tetsuo Ueda, Masanori Niki, Yoshinori Mitamura, Hiroto Ishikawa, Fumi Gomi, Shigehiko Kitano, Hidetaka Noma, Masahiko Shimura, Shozo Sonoda, Osamu Sawada, Masahito Ohji, Kozo Harimoto, Masaru Takeuchi, Yoshihiro Takamura, Mineo Kondo, Taiji Sakamoto   +19 more
doaj   +1 more source

The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging

Advanced Science, EarlyView.
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma, Rui Guo, Dongfeng Niu, Yufei Song, Zhenyao Zhang, Xiangxi Meng, Lili Mao, Haifeng Huang, Hua Zhu, Zhi Yang, Teli Liu   +10 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Single‐Cell Transcriptomic Analysis of Tumor Heterogeneity and the Microenvironment in Pseudomyxoma Peritonei

Advanced Science, EarlyView.
This study presents a single‐cell atlas of pseudomyxoma peritonei spanning primary and paired metastatic lesions. Distinct epithelial substates, stromal remodeling, immune exclusion, lipid metabolic reprogramming, and a candidate angiogenic network were identified in metastatic lesions.
Xi Li, Lei Wang, Lei Ai, Zimeng Li, Zhaochangci Chen, Yuchen Luo, Tianran Zhang, Mengjia Liao, Songhao Wang, Jiajia Cui, Ke Liu, Chengxian Guo, Guodong Liu, Jiye Yin, Wei Wu   +14 more
wiley   +1 more source

A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA.

PLoS Medicine, 2008
BackgroundVascular endothelial growth factor-A (VEGF) is one of the key regulators of tumor development, hence it is considered to be an important therapeutic target for cancer treatment. However, clinical trials have suggested that anti-VEGF monotherapy
Kiyoshi Masuda, Shigetada Teshima-Kondo, Mina Mukaijo, Naoko Yamagishi, Yoshiko Nishikawa, Kensei Nishida, Tomoko Kawai, Kazuhito Rokutan   +7 more
doaj   +1 more source